Progenity Inc. (NASDAQ: PROG) Receives Four Patents Covering Gastrointestinal Technologies for Therapeutics delivery

Progenity Inc. (NASDAQ: PROG) has received four patents from the US Patent and trademark Officer associated with its ingestible technologies for therapeutics delivery through the gastrointestinal tract.

USPTO issues Progenity with four patents 

The company received US patent No. 11,007,356 titled, “Ingestible device for delivery of therapeutic agent to the gastrointestinal tract.”  The patent covered methods and techniques for therapeutic drug delivery into gastrointestinal tissue for systemic uptake. Progenity’s Oral Biotherapeutic Delivery System (OBDS) is a systemic, needle-free biotherapeutics delivery through an ingestible device the company is currently developing. So far, preclinical research has shown that the OBDS can achieve protein bioavailability of up to 44%.

The other issued USPTO Patent No. 11,033,490 covers gastrointestinal tract conditions inflammatory conditions treatment with Janus Kinase inhibitor. This patent covers techniques for Ulcerative colitis treatment using an ingestible device that distributes Janus kinase inhibitor to the large intestine’s proximal section. In addition, the company is planning to commence studies of the PGN 600 program for novel formulation tofacitinib targeted delivery to disease sites using the Drug Delivery System currently under development as part of its gastrointestinal tract therapeutic program.

Progenity receives gastrointestinal tract targeted therapies patents 

Additionally, the company received US Patent No. 10980,739 titled, “Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor,” and US Patent No. 11,134,889 titled, “Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor.”  The patents are part of Progenity’s gastrointestinal tract targeted therapies portfolio that includes over 170 pending and issued patents for around 17 inflammation bowel conditions targets that include IL12/23, TNF-alpha, and integrins. Progenity’s patent portfolio comprises 96 patent families.

Progenity CEO Eric d’Esparbes said, “We believe we hold one of the most robust ingestible device patent portfolios. The addition of these recent patents further strengthens our intellectual property position and underscores our commitment to innovation in advancing therapeutic discovery, development, and delivery.”